ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 7ÔÂ2ÈÕ£¬£¬£¬£¬£¬£¬»ªê»ÖÐÌìÐû²¼£¬£¬£¬£¬£¬£¬ÆäÓÅÌæµÂ¡עÉäÒºÖÎÁÆHER2ÒõÐÔÈéÏÙ°©ÄÔ×ªÒÆ£¨BCBM£©µÄÃÀ¹ú2ÆÚÁÙ´²ÊÔÑ飨BG01-2402£©ÒÑ»ñµÃÃÀ¹úFDAÅú×¼¡£¡£¡£¡£¸ÃÑо¿Ö¼ÔÚÆÀ¹ÀÓÅÌæµÂ¡עÉäÒºÁªºÏ¿¨ÅàËû±õÖÎÁÆHER2ÒõÐÔBCBM»¼ÕßµÄÂÄÚºÍÈ«ÉíÁÆÐ§¼°Çå¾²ÐÔ¡£¡£¡£¡£
2. 7ÔÂ1ÈÕ£¬£¬£¬£¬£¬£¬ÉϺ£Ò½Ò©£¨601607£©Ðû²¼Í¨¸æ³Æ£¬£¬£¬£¬£¬£¬¿ËÈÕ£¬£¬£¬£¬£¬£¬¹«Ë¾È«×Ê×Ó¹«Ë¾ÉϺ£ÉÏÒ©ÐÅÒêÒ©³§ÓÐÏÞ¹«Ë¾ÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÏ·¢µÄ¹ØÓÚWST03ÖÆ¼Á£¨½ºÄÒ£©µÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬£¬£¬£¬£¬£¬½«ÓÚ½üÆÚÆô¶¯º£ÄÚIÆÚÁÙ´²ÊÔÑé¡£¡£¡£¡£Í¨¸æÏÔʾ£¬£¬£¬£¬£¬£¬WST03ÊÇÒõµÀÓÃ΢Éú̬»î¾úÖÆ¼Á£¬£¬£¬£¬£¬£¬ÄâÓÃÓÚÖÎÁÆÏ¸¾úÐÔÒõµÀ²¡£¡£¡£¡£¨BV£©¡£¡£¡£¡£
3. 6ÔÂ29ÈÕ£¬£¬£¬£¬£¬£¬CDE¹Ù·½ÍøÕ¾ÏÔʾ£¬£¬£¬£¬£¬£¬±±¾©ÖÐÒò¿Æ¼¼ÓÐÏÞ¹«Ë¾ZVS101e×¢ÉäÒºÒÑÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖÃûµ¥£¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁƽᾧÑùÊÓÍøÄ¤±äÐÔ£¨BCD£©¡£¡£¡£¡£×ÊÁÏÏÔʾ£¬£¬£¬£¬£¬£¬ZVS101eÊÇÖÐÒò¿Æ¼¼¿ª·¢µÄÒ»¿î»ùÒòÌæ»»ÖÎÁƺòѡҩÎï¡£¡£¡£¡£
4. 6ÔÂ28ÈÕ£¬£¬£¬£¬£¬£¬Ñ±Â¹ÉúÎïÐû²¼Æä×ÔÖ÷Ñз¢µÄÈ«ÈËÔ´°ÐÏòGPRC5DµÄCAR-T²úÆ·RD118µÄÐÂÒ©ÁÙ´²ÊÔÑéÉêÇ루IND£©»ñÖйú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA£©Ä¬Ê¾ÔÊÐí£¬£¬£¬£¬£¬£¬ÄâÓÃÓÚÖÎÁƸ´·¢/ÄÑÖÎÐÔ¶à·¢ÐÔ¹ÇËèÁö£¨RRMM£©¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬£¬£¬ËÕÖݰ²Ììʥʩҽҩ¿Æ¼¼ÓÐÏÞ¹«Ë¾Ðû²¼Íê³É½üÒÚÔªAÂÖÈÚ×Ê¡£¡£¡£¡£±¾ÂÖÈÚ×ÊÓɹúͶ´´ÒµÁìͶ£¬£¬£¬£¬£¬£¬ÀϹɶ«ºÍÈð´´Í¶SCA3¹¤Òµ»ù½ð¸úͶ£¬£¬£¬£¬£¬£¬Ö§³Ö°²ÌìÊ¥Ê©ÍÆ¶¯Ð¼¼ÊõÑз¢¡¢ÉÌÒµ»¯Éú²úʵÑé¡¢¹ú¼Ê»¯Ä±»®Õ½ÂԽṹµÈ¡£¡£¡£¡£±¾ÂÖËùļ×ʽð½«ÓÃÓÚ¼ÓËÙÍÆ½øÕë¶Ô¶ÅÊϼ¡ÓªÑø²»Á¼¡¢¼¹ËèСÄÔ¹²¼Ãʧµ÷¡¢ºàÍ¢¶ÙÎ赸֢µÈ˳Ӧ֢µÄ²úÆ·²¢ÉêÇë×¢²áÁÙ´²ÊÔÑ飬£¬£¬£¬£¬£¬Íƶ¯¶à¸öºóÐøÁ¢Òì¹ÜÏߵIJúÆ·¿ª·¢£¬£¬£¬£¬£¬£¬Ôö½ø¹ú¼ÊÏàÖú¡£¡£¡£¡£
2. 7ÔÂ1ÈÕ£¬£¬£¬£¬£¬£¬Ä¬É³¶«ÓëOrion CorporationÅäºÏÐû²¼£¬£¬£¬£¬£¬£¬Ë«·½ÒѾÐÐʹѡÔñȨ£¬£¬£¬£¬£¬£¬½«ÕýÔÚ¿ª·¢µÄCYP11A1ÒÖÖÆ¼Áopevesostat(MK-5684/ODM-208)ÒÔ¼°ÆäËûÔÚÑÐCYP11A1ÒÖÖÆ¼ÁºòѡҩÎïµÄÁªºÏ¿ª·¢¡¢ÉÌÒµ»¯È¨Òæ×ªÎªÄ¬É³¶«¶À¼ÒÈ«ÇòÔÊÐíÈ¨Òæ¡£¡£¡£¡£
1. 6ÔÂ25ÈÕ£¬£¬£¬£¬£¬£¬½ÒÏþÔÚNature BiotechnologyÔÓÖ¾ÉϵÄÒ»ÏîÑо¿ÖУ¬£¬£¬£¬£¬£¬À´×ÔҮ³´óѧµÄ¿ÆÑ§¼ÒÍŶӷ¢Ã÷ÁËÒ»ÖÖÄܹ»ÈÃNKϸ°û¸üÓÐÓõضԿ¹°©Ö¢µÄÒªÁì¡£¡£¡£¡£Ñо¿Ö°Ô±³Æ£¬£¬£¬£¬£¬£¬ÕâÒ»·¢Ã÷ÓÐÍûΪʵÌåÁöÖÎÁÆ´øÀ´Í»ÆÆ¡£¡£¡£¡£
[1]Peng, L., Renauer, P.A., Sferruzza, G. et al. In vivo AAV¨CSB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02282-4
Ïà¹ØÐÂÎÅ